The results are now being published in Cancer Research and are part of a project funded by the Austrian Science Fund FWF. The antibodies produced during the project belong to a class that also plays a key role in the development of allergic reactions. Consequently, the results will be a key focal point at the 1st International AllergoOncology Symposium, which is to be held today in Vienna, Austria.
People who suffer from allergies are well acquainted with immunoglobulin E (IgE). It is this class of antibodies that plays a key role in causing an allergy sufferer's immune system to overreact. Oncologists too are very familiar with IgE. Numerous in-depth studies have shown that those with raised levels of IgE are much less likely to suffer from certain types of cancer. Or in other words – allergy sufferers are at a lower risk of developing cancer.
ALLERGY & CANCER
"In actual fact, the IgE produced during an allergic reaction does not attack cancer tumours but instead attacks allergens, for example pollen", explains the study's leader, Prof. Erika Jensen-Jarolim, head of the Department of Pathophysiology at the Medical University of Vienna. "The fact that IgE nevertheless acts against tumours is more of a fortunate side-effect of the highly efficient characteristic of this antibody class. It was our aim to make this antibody class, which is typical for allergies, act directly against tumours. At the same time, we wanted to encourage the long-term production of IgE in the body by means of active immunisation."
Prof. Jensen-Jarolim's group recently succeeded in achieving the latter – active immunisation against certain types of tumour – in mice. However, due to the selected type of immunisation (injection below the abdominal wall) the antibodies that were produced belonged to the IgG class. This type of antibody produces a much more limited and shorter-term effect against tumours than IgE antibodies.
THROUGH THE STOMACH
Prof. Jensen-Jarolim used one of her group's earlier successes – achieved as part of another FWF project on food allergies – to ensure that immunisation resulted in the intended activation of IgE. These findings prove that food proteins are effective in inducing IgE-dependent immune reactions when they withstand the acidic environment of the stomach.
Prof. Jensen-Jarolim's team therefore fed mice a peptide very similar to a tumour peptide while reducing acidification in the stomach, thereby hindering digestion of the peptide. As a result, a type of allergic reaction was triggered against this tumour-like peptide – the mice produced tumour-specific IgE antibodies. The result is the world’s first active IgE-stimulating tumour vaccination.
From Prof. Jensen-Jarolim's point of view, the publication of this work in Cancer Research comes at a the perfect time – just as the 1st International AllergoOncology Symposium starts on 16th April in Vienna. This symposium, which she initiated and organised, will be the first time that specialists from the U.K., France, Italy, Canada, Austria and the U.S. have been brought together to analyse and discuss the links between allergies and cancer. The topics under discussion range from the use of allergic reactions to treat cancer to the application of mimotopes for active immunisation against cancer tumours. By providing ongoing support for their work, the FWF has also helped establish this new medical field in Austria and on a global scale.
Image and text will be available online from Monday, 16th April 2007, 09.00 a.m. CET onwards: http://www.fwf.ac.at/en/public_relations/press/pv200704-en.html
Till C. Jelitto | alfa
New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center
Pain: Perception and motor impulses arise in the brain independently of one another
12.12.2018 | Technische Universität München
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Ecology, The Environment and Conservation
13.12.2018 | Life Sciences
13.12.2018 | Physics and Astronomy